ESALF News and Press, Eisai Co Ltd From 06/03/24

Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform TOKYO, June 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment bus...

2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...

"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea TOKYO and CAMBRIDGE, Mass., May 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized an...

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Onco...

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan TOKYO, May 22, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject...

2024-05-16 21:14:05 ET Eisai Co Ltd. (ESALF) Q4 2024 Results Conference Call May 16, 2024 2:00 AM ET Company Participants Haruo Naito - CEO, Representative Corporate Officer & Director Keisuke Naito - SVP, Chief Strategy, Planning & Ecosystem Officer and Acti...

2024-05-15 12:52:06 ET More on Eisai Eisai: All About Lenvima And Leqembi Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report Historical earnings dat...

2024-05-15 10:39:47 ET More on Eisai Eisai: All About Lenvima And Leqembi Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report Historical earnings dat...

2024-05-15 09:24:14 ET More on Eisai Eisai: All About Lenvima And Leqembi Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report Historical earnings dat...

2024-05-15 07:44:07 ET More on Biogen, Eisai Co., Ltd., etc. Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) Biogen says uptake for Alzheimer’s therapy...